Amgen may not have an approved GLP-1 treatment just yet, but that could change in the future.

Amgen (AMGN) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the ...

The market expects Amgen (AMGN) to deliver a year-over-year decline in earnings on higher revenues when it reports results ...

In its upcoming report, Amgen (AMGN) is predicted by Wall Street analysts to post quarterly earnings of $4.74 per share, ...

Amgen’s AMGN stock has risen almost 16% in a month. A lot of this price increase is due to strong third-quarter 2025 results, wherein both the top and bottom lines exceeded expectations. Amgen also ...

Amgen ends its rocatinlimab partnership, returning control to Kyowa Kirin, citing strategy changes, weaker Phase 3 results ...

If you buy and hold a stock for many years, you'd hope to be making a profit. But more than that, you probably want ...

Amgen says its MariTide obesity drug helped patients maintain weight loss for a second year, with good safety and fewer side effects.

Amgen Inc. Buy thesis: strong pipeline, 12% Q3 2025 revenue growth and MariTide obesity upside. Click for this updated look ...

Amgen's weight management candidate looks very promising. The large biotech boasts a deep pipeline beyond that segment. Amgen's dividend looks great, and the stock is reasonably valued. Even so, there ...